Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Investors who had become concerned about an obesity market slowdown, as well as Novo’s competitive position, breathed a sigh of relief.

Lilly is looking to take market share from rival Novo Nordisk in the obesity market after a head-to-head trial showed Zepbound helped patients lose more weight than Wegovy. The market for these ...

All hands on deck' at Lilly as competitors come for obesity market Lilly has invested billions into manufacturing capabilities to support the launch of obesity drug Zepbound and other phase 3 ...

Furthermore, considering the substantial investment made by big pharma, the obesity market is highly capital intensive, a great challenge for emerging players, contends the firm. Such challenges ...

It's just—this market is quite different." Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's The question of just how to reckon with the scope of the obesity ...

Obesity care sales increased by 57%, driven by significant growth in both North America and international operations. Novo Nordisk AS (NYSE:NVO) maintained its leadership in the GLP-1 market ...

Novo Nordisk's 2024 earnings exceeded estimates, with 25% revenue growth and strong performance in diabetes, obesity, and rare disease segments. The market overreacted to CagriSema trial results ...

Investors in the obesity drug market can breathe a sigh of relief—but not for long.